LYRA

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).

Wall Street analysts forecast LYRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LYRA is 16.00 USD with a low forecast of 16.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Lyra Therapeutics Inc revenue for the last quarter amounts to 25.00K USD, decreased -87.18 % YoY.

Lyra Therapeutics Inc. EPS for the last quarter amounts to -3.38 USD, decreased -62.73 % YoY.

Lyra Therapeutics Inc (LYRA) has 30 emplpoyees as of December 17 2025.

Today LYRA has the market capitalization of 6.85M USD.